摘要
目的探讨奎硫平治疗老年期首发精神分裂症患者的疗效及安全性。方法将64例老年期首发精神分裂症患者随机分为两组各32例,分别服用奎硫平、奋乃静治疗,疗程8w。于治疗前及治疗第2w、4w、6w、8w末采用简明精神病量表评定临床疗效,副反应量表评定不良反应。结果治疗8w末奎硫平组显效率84.4%,奋乃静组为81.3%;简明精神病量表评分两组治疗2w末起均较治疗前有极显著性下降(P<0.01),并随着治疗时间的延续呈持续性下降。两组间同期评分比较均无显著性差异(P均>0.05)。奎硫平组肌强直、震颤、扭转性痉挛、视物模糊不良反应发生率均显著低于奋乃静组(P均<0.05)。结论奎硫平治疗老年首发精神分裂症疗效显著,安全性高,依从性高。
Objective To exploe the efficacy and safety of quetiapine in the treatment of. Methods 64 gerontic patients with first-episode schizophrenia were divided randomly into quetiapine and prephenazine group（each n=32） for 8 weeks.Clinical efficacies were assessed with The Brief Psychiatric rating Scale（BPRS） and adverse effects with the Treatment Emergent Symptom Scale（TESS） before treatment and at the end of the 2nd,4th,6th and 8th week treatment. Results At the end of the 8th week, excellence rate was 84.4% in the quetiapine and 81.3% in the prephenazine group respectively; since the end of 2nd week, scores of the BPRS of both groups lowered very significantly compared with pretreatment （P〈0.01）, and along with treatment did continously. There was no significant difference in synchronization scores between the 2 groups （P〈0.05）. incidences of such adverse effects as myotonia, tremor, adversive cramp and vision blurring were significantly lower in the the quetiapine than in the prephenazine group（P〈0.05）. Conclusion Quetiapine has significant efficacy, higher safety and better compliance.
出处
《临床心身疾病杂志》
CAS
2007年第5期407-408,共2页
Journal of Clinical Psychosomatic Diseases
